Benitec Biopharma Ltd ADR (BNTC)

Currency in USD
13.660
-0.180(-1.30%)
Closed·
13.930+0.270(+1.98%)
·
BNTC Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BNTC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.60013.990
52 wk Range
9.09017.150
Key Statistics
Prev. Close
13.66
Open
13.99
Day's Range
13.6-13.99
52 wk Range
9.09-17.15
Volume
22.94K
Average Volume (3m)
53.7K
1-Year Change
44.09%
Book Value / Share
3.71
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BNTC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.857
Upside
+81.97%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Benitec Biopharma Ltd ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Benitec Biopharma Ltd ADR Company Profile

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Benitec Biopharma Ltd ADR SWOT Analysis


Gene Therapy Promise
Benitec Biopharma's BB-301 shows encouraging results in OPMD trial, with consistent improvements in swallowing capability and patient-reported outcomes
Clinical Milestones
Explore the company's progress as it advances to the high-dose cohort, with potential updates expected in Q4 2025 that could significantly impact stock performance
Financial Fortitude
Learn about Benitec's robust liquidity position, with a current ratio of 14.8 and recent $30 million capital raise, supporting ongoing clinical development
Market Potential
Analyst price targets range from $17 to $35, suggesting significant upside potential as Benitec's gene therapy platform shows promise for treating rare diseases
Read full SWOT analysis

Compare BNTC to Peers and Sector

Metrics to compare
BNTC
Peers
Sector
Relationship
P/E Ratio
−9.5x−1.9x−0.7x
PEG Ratio
−0.680.080.00
Price/Book
3.7x6.1x2.6x
Price / LTM Sales
-40.9x3.4x
Upside (Analyst Target)
102.3%226.5%36.2%
Fair Value Upside
Unlock6.7%4.1%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.857
(+81.97% Upside)

Earnings

Latest Release
Sep 22, 2025
EPS / Forecast
-0.39 / -116.14
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

BNTC Income Statement

People Also Watch

40.01
EXEL
-0.20%
158.28
INSM
+0.71%
38.29
KNSA
-0.52%
2.400
JSPR
-3.61%
2.450
ORMP
+0.41%

FAQ

What Stock Exchange Does Benitec Biopharma ADR Trade On?

Benitec Biopharma ADR is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Benitec Biopharma ADR?

The stock symbol for Benitec Biopharma ADR is "BNTC."

What Is the Benitec Biopharma ADR Market Cap?

As of today, Benitec Biopharma ADR market cap is 358.58M.

What Is Benitec Biopharma ADR's Earnings Per Share (TTM)?

The Benitec Biopharma ADR EPS (TTM) is -1.05.

From a Technical Analysis Perspective, Is BNTC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Benitec Biopharma ADR Stock Split?

Benitec Biopharma ADR has split 9 times.

How Many Employees Does Benitec Biopharma ADR Have?

Benitec Biopharma ADR has 19 employees.

What is the current trading status of Benitec Biopharma ADR (BNTC)?

As of 07 Oct 2025, Benitec Biopharma ADR (BNTC) is trading at a price of 13.660, with a previous close of 13.66. The stock has fluctuated within a day range of 13.600 to 13.990, while its 52-week range spans from 9.090 to 17.150.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.